Q2 Earnings Forecast for UNCY Issued By HC Wainwright

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Unicycive Therapeutics in a note issued to investors on Tuesday, May 27th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.08) for the quarter. HC Wainwright has a "Strong-Buy" rating and a $9.00 price target on the stock. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics' Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.25) EPS, Q1 2026 earnings at $0.27 EPS, Q2 2026 earnings at $0.29 EPS, Q3 2026 earnings at $0.37 EPS, FY2026 earnings at $1.41 EPS, FY2027 earnings at $2.89 EPS, FY2028 earnings at $2.75 EPS and FY2029 earnings at $2.06 EPS.

Separately, Guggenheim began coverage on shares of Unicycive Therapeutics in a research note on Monday, April 21st. They issued a "buy" rating and a $6.00 price target for the company.

Unicycive Therapeutics Stock Down 0.3%

UNCY traded down $0.00 during midday trading on Thursday, hitting $0.59. The company had a trading volume of 759,158 shares, compared to its average volume of 1,504,858. Unicycive Therapeutics has a 52 week low of $0.20 and a 52 week high of $0.96. The company has a market capitalization of $70.93 million, a price-to-earnings ratio of -0.61 and a beta of 2.14. The stock's 50 day moving average price is $0.59 and its 200 day moving average price is $0.62.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.09.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in UNCY. Nantahala Capital Management LLC grew its holdings in shares of Unicycive Therapeutics by 268.5% during the fourth quarter. Nantahala Capital Management LLC now owns 10,391,994 shares of the company's stock valued at $8,253,000 after buying an additional 7,571,636 shares during the last quarter. Vivo Capital LLC grew its holdings in shares of Unicycive Therapeutics by 123.0% during the fourth quarter. Vivo Capital LLC now owns 9,970,152 shares of the company's stock valued at $7,918,000 after buying an additional 5,500,000 shares during the last quarter. Octagon Capital Advisors LP grew its holdings in shares of Unicycive Therapeutics by 16.8% during the fourth quarter. Octagon Capital Advisors LP now owns 10,000,000 shares of the company's stock valued at $7,942,000 after buying an additional 1,441,000 shares during the last quarter. Acuta Capital Partners LLC grew its holdings in shares of Unicycive Therapeutics by 16.4% during the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock valued at $1,829,000 after buying an additional 323,801 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Unicycive Therapeutics by 30.3% during the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock valued at $417,000 after buying an additional 122,089 shares during the last quarter. 40.42% of the stock is currently owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.